Founded in 2019 by Recursion Pharmaceuticals alumnus Viswa Colluru, Enveda operates on the premise that nature’s own chemistry remains an untapped reservoir for potent pharmaceuticals. By deploying advanced AI to identify and optimize compounds derived from the natural world, the startup aims to bypass the traditional, labor-intensive process of synthetic drug creation.
Enveda Raises $311 Million to Fast-Track AI-Driven Natural Drug Discovery
A valuation of $2 billion marks a doubling in worth for Enveda, the biotech startup leveraging artificial intelligence to mine plants and microbes for therapeutic compounds. The company’s $311 million Series E funding round, led by Catalio Capital Management, signals growing investor confidence in AI-derived medicine moving toward clinical reality.
While the broader AI drug discovery sector awaits its first FDA-approved success, Enveda is actively transitioning from research to human testing. The company currently has candidates in clinical trials, including treatments for severe skin conditions and a therapeutic candidate aimed at maintaining weight loss following the cessation of GLP-1 medications.
Comments (0)
No comments yet. Be the first!